Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria - Test2 - elhamkhani - TriplyDB

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

http://www.wikidata.org/entity/Q30431214

about

CCN: core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma?Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy Present and future in the treatment of diabetic kidney disease HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease Hepatic radiation toxicity: avoidance and amelioration Role of bone morphogenetic protein-7 in renal fibrosis Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets Increased CCN2, substance P and tissue fibrosis are associated with sensorimotor declines in a rat model of repetitive overuse injury.2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis A soluble factor from Trypanosoma cruzi inhibits transforming growth factor-ß-induced MAP kinase activation and gene expression in dermal fibroblasts.From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action.Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-β1, and vascular endothelial growth factor.Therapeutic targets for treating fibrotic kidney diseases CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells.Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction.Effects of Minocycline on Urine Albumin, Interleukin-6, and Osteoprotegerin in Patients with Diabetic Nephropathy: A Randomized Controlled Pilot Trial.Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy.Connective tissue growth factor gene expression and decline in renal function in lupus nephritis Diabetic nephropathy: What does the future hold?Comprehensive approach to diabetic nephropathy.The insulin-like growth factor system in chronic kidney disease: Pathophysiology and therapeutic opportunities.Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization Implications of treatment that target protective mechanisms against diabetic nephropathy Targeting pericyte differentiation as a strategy to modulate kidney fibrosis in diabetic nephropathy.Transforming growth factor-beta and the glomerular filtration barrier.High glucose-induced cytoplasmic translocation of Dnmt3a contributes to CTGF hypo-methylation in mesangial cells.RPTOR, a novel target of miR-155, elicits a fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF.The coordinated roles of miR-26a and miR-30c in regulating TGFβ1-induced epithelial-to-mesenchymal transition in diabetic nephropathy.Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013 Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.Antifibrotic treatment and other new strategies for improving renal outcomes What are new avenues for renal protection, in addition to RAAS inhibition?Red carpeting the newer antidiabetics.Anti-fibrosis therapy and diabetic nephropathy.Molecular targets for treatment of kidney fibrosis.Resident mesenchymal cells and fibrosis.

P2860

Q26779818-744F1554-05FD-45DF-98C8-71692EEDE144 Q26784039-E93708AF-7743-4D6D-9443-C63D943E6180 Q26864133-0019E40C-CD0D-4632-8B4B-55DCFD42460A Q26996407-DCA0DF43-8763-438B-9FE8-D52B87082F33 Q27023687-97062A7B-426E-4E91-87E9-CC471699C95F Q28080865-7E983CF4-07BA-449A-81C8-717D533E2347 Q28083781-9FB8233C-1958-4BEC-8CDA-B45F35041B16 Q28086840-23773CFD-8562-45E2-983D-90676D9209D1 Q28254386-F0EBECAD-804B-4525-9DFB-C3C154C5BCC1 Q28392878-3295858F-D357-48E3-A1A6-FA1737F89898 Q30239808-08B7C64F-94D0-41F7-90D7-A4DC16366A92 Q30423005-A414F5C6-EA2B-4730-8A8C-E8829D8EE531 Q33906324-6D989D89-2925-4CDB-940E-E69266A1833F Q34023102-155EC760-3BA2-4A6D-94B0-152989299A36 Q34391213-0624BEAF-F944-4FCF-B60D-4398D3D5476A Q34482573-0772BE3E-1479-4CA5-A067-8CD8977661DF Q35079607-384119E5-0262-455F-83F2-57C3369756AA Q35134602-39F52215-6197-4391-B072-19F25430170D Q35799748-57F5F93E-44D4-4FC5-9C28-1E36F371A699 Q35971663-972C8C87-9638-4F32-9A34-4EB56F43E849 Q35985704-1387AF33-A26B-4AC5-9A2E-C6B9A6E244DB Q36224342-D8546CF9-27C9-4C39-BE26-0C2149C7857A Q36441616-AC89DA55-65D0-4B11-80CB-A7042469B1B5 Q36466019-03E6E2C2-40A1-4E1D-BC7A-2ECAC4EB3F15 Q36468522-7AFA07D9-F522-4687-B490-431501C60331 Q36578825-8907B2DD-C383-4ED7-A64B-64ADDEB4A3BE Q36645971-C0F54A4B-4858-4269-8432-922653C69624 Q36908400-5AF6F2A7-2CF2-494F-9CD0-E123405192CB Q37089424-E21862DB-8B57-4A82-A3DB-88938DFDDE02 Q37153862-7370B00D-2979-406C-AF61-FFA241462809 Q37237979-559D53EE-63DD-4D71-BA12-6776039F7AF6 Q37427986-97EA6A8D-7517-432B-BED5-1D113AB5E2FA Q37496388-58F3474B-8976-4A1B-8106-1E74D892B202 Q37627887-40934824-02CD-4BE5-8095-16C74603FF37 Q37887401-9B4C4357-555B-4D5A-8FC7-E9B4BB86B68A Q37980677-A76A8AC9-2AB7-481A-8B8A-E13AB82968FC Q38013105-2887D4D3-9F21-47ED-8455-85A33A0A23B8 Q38014361-E67E95E4-9B81-4C34-8A57-A694FB5ECD56 Q38062404-90A87A1A-C401-4764-8A93-C6466090A589 Q38065650-2932F823-904C-48DC-BD84-1921B2B0CEB1

P2860

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

http://www.wikidata.org/entity/Q30431214

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase 1 study of anti-CTGF mon ...... diabetes and microalbuminuria

@ast

Phase 1 study of anti-CTGF mon ...... diabetes and microalbuminuria

@en

type

label

Phase 1 study of anti-CTGF mon ...... diabetes and microalbuminuria

@ast

Phase 1 study of anti-CTGF mon ...... diabetes and microalbuminuria

@en

prefLabel

Phase 1 study of anti-CTGF mon ...... diabetes and microalbuminuria

@ast

Phase 1 study of anti-CTGF mon ...... diabetes and microalbuminuria

@en

P1433

Q30431214-EE881699-17DE-4729-B697-F771AE30E6AF

P1476

Q30431214-EC7043D3-54E6-4B67-9EF3-A2BA93644A03

P2093

Q30431214-11A7D574-7369-4F63-B38E-2D6F94DE586E

Q30431214-27464AFA-9A41-49EC-892D-F69866BB7C8A

Q30431214-434DF9FE-CBF4-495E-B1F1-5A97EBE3EC11

Q30431214-46111A10-74FA-415A-BB01-547F87D0A4CF

Q30431214-6139F05B-060E-4529-B3EA-3E69EB012E77

Q30431214-7C05B6F7-AF6A-4733-A6CF-93075B5C3665

Q30431214-863B7E84-A697-4BDB-8C4E-44EE9087F330

Q30431214-891445BE-8ABE-430A-B3AE-412FD8428D90

Q30431214-DBB8F863-99F5-46B3-BD6D-FF6497D823D1

Q30431214-EE41141E-B686-4D86-8DBB-19C3F6CEBAFE

P2860

Q30431214-01C386F1-8303-4B3F-8D92-556CADEF199A

Q30431214-045BC6CC-A046-4AD6-9749-5CB78DC8B8BD

Q30431214-203A5D51-F7CB-47BC-AA0C-363D6FE940D3

Q30431214-266F7559-90A6-475D-A1E2-B374D8C2E62C

Q30431214-2B9496A9-7B1F-4A1D-9058-8F29CF0CEF38

Q30431214-34BA3D65-C87A-4E0A-921C-5223EA4102ED

Q30431214-3B5D0837-6823-46B3-BDF3-1ECF6E81A1A1

Q30431214-3B9A4FA0-7A7C-45BE-B497-321BE6F7F78B

Q30431214-3C037F79-F1C7-41BB-BBB5-2EF2A4832ABD

Q30431214-42030D90-05CF-4494-B6FB-AEE2F2048295

P304

Q30431214-37D7B2DB-9387-44AC-B534-82D561C363FA

P31

Q30431214-8205125B-F060-4F14-8F90-EA8623738A5F

P356

Q30431214-DF37763D-8974-4353-B523-25F1832A280A

P433

Q30431214-87DB4869-FBAA-4BC5-A060-FBA0E6C61312

P478

Q30431214-203AA9F5-2D93-4064-BA19-C2207DB79620

P577

Q30431214-5C048335-78D8-4B29-86F4-BC0FD93BF9EB

P5875

Q30431214-629F5CC1-B8E4-412D-84D7-FAB42BF62704

P698

Q30431214-3053E5C8-F082-4C0E-8BA5-DD14FF7BCE9D

P921

Q30431214-48FF3F54-706D-4952-ADD0-9E12ED2395BC

P932

Q30431214-C8F6C1E1-73DC-4CE0-93FC-4F2269154B45

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Phase 1 study of anti-CTGF mon ...... diabetes and microalbuminuria

@en

P2093

Carlos Arauz-Pacheco

http://www.w3.org/2001/XMLSchema#string

Dongxia Li

http://www.w3.org/2001/XMLSchema#string

K Lea Sewell

http://www.w3.org/2001/XMLSchema#string

Mark E Williams

http://www.w3.org/2001/XMLSchema#string

Pedro R Urquilla

http://www.w3.org/2001/XMLSchema#string

Sharon G Adler

http://www.w3.org/2001/XMLSchema#string

Sherwyn Schwartz

http://www.w3.org/2001/XMLSchema#string

Thomas B Neff

http://www.w3.org/2001/XMLSchema#string

Tyson Lee

http://www.w3.org/2001/XMLSchema#string

Warren K Bolton

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II.

Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.

Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.

Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair

Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways.

Structural and functional properties of CCN proteins.

P304

1420-1428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.09321209

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44648565

http://www.w3.org/2001/XMLSchema#string

P698

20522536

http://www.w3.org/2001/XMLSchema#string

P921

P932

2924405

http://www.w3.org/2001/XMLSchema#string